Condition: Locally Advanced or Metastatic Breast Cancer · Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
This Phase III, randomized, open label, multicenter study will evaluate the efficacy and safety of SIM0270 combined with everolimus compared to physician's choice of treatment in subjects with ER+/HER2- locally advanced or metastatic breast cancer who have had previous treatment with CDK4/6 inhibitor.
This description comes directly from the study's public registry record.
JING WANG · 18624010252 · wangjing16f919@zaiming.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hispital of Bengbu Medical University | Bengbu, Anhui, China | Recruiting |
| Anhui Provincial Cancer Hospital | Hefei, Anhui, China | Recruiting |
| The First Affiliated Hispital of Anhui Medical University | Hefei, Anhui, China | Recruiting |
| Maanshan People's Hospital | Maanshan, Anhui, China | Recruiting |
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
| The First Medical Center of PLA Ggeneral Hospital | Beijing, Beijing Municipality, China | Recruiting |
| The First Affiliated Hospital of Chongqing Medical University | Chongqing, Chongqing Municipality, China | Recruiting |
| The Second Affiliated Hospital of Chongqing Medical University | Chongqing, Chongqing Municipality, China | Recruiting |
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Recruiting |
| Fujian Provincial Hospital | Fuzhou, Fujian, China | Recruiting |
| The Second Affiliated Hospital of Fujian Medical University | Quanzhou, Fujian, China | Not Yet Recruiting |
| Gansu Provincial Cancer Hospital | Lanzhou, Gansu, China | Recruiting |
+ 48 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06680921